TY - JOUR AB - The present study aimed to investigate the expression levels and clinical significance of microRNA (miR)‑203 and miR‑133b in laryngeal carcinoma. A total of 154 patients with laryngeal carcinoma (research group) along with 100 healthy individuals (control group) were enrolled in the study. The patients were admitted to Yidu Central Hospital of Weifang (Weifang, China) from February 2016 to October 2018. Fasting venous blood (5 ml) was extracted from all subjects to determine the expression levels of serum miR‑203 and miR‑133b by reverse transcription‑quantitative polymerase chain reaction (PCR) and to compare them among patients with different pathological characteristics. Receiver operating characteristic (ROC) curves were plotted to analyze the diagnostic values of miR‑203 and miR‑133b for laryngeal carcinoma. The research group showed significantly lower expression levels of miR‑203 and miR‑133b than the control group (P<0.05). According to ROC curve analysis, when the cut‑off value was 0.659, the sensitivity and specificity of miR‑203 in diagnosing laryngeal carcinoma were 60.00 and 90.26%, respectively, whereas when the cut‑off value was 1.398, the sensitivity and specificity of miR‑133b were 55.00 and 87.66%, respectively. The sensitivity and specificity of the joint detection were 70.00 and 83.77%, respectively, when the cut‑off value was 0.416. In the research group, miR‑203 was expressed significantly different in patients with different pathological stages and tumor types (P<0.050). The expression of miR‑133b varied significantly in patients with different pathological stages, differentiation degrees and lymph node metastasis (P<0.050). In conclusion, miR‑203 and miR‑133b were expressed at low levels in patients with laryngeal carcinoma. The expression of miR‑203 was related to tumor‑node‑metastasis (TNM) stage and tumor type, whereas the expression of miR‑133b was related to TNM stage, differentiation degree, as well as lymph node metastasis. Joint detection of miR‑203 and miR‑133b is expected to be an excellent marker for the diagnosis and treatment of laryngeal carcinoma. AD - Department of Otolaryngology, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China Department of Return Visit Office, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China Department of Pathology, Jilin Cancer Hospital, Changchun, Jilin 130012, P.R. China AU - Zhao,Na AU - Liu,Hongjun AU - Zhang,Aifen AU - Wang,Min DA - 2020/11/01 DO - 10.3892/ol.2020.12076 IS - 5 JO - Oncol Lett KW - miR‑203 miR‑133b laryngeal carcinoma clinical pathology PY - 2020 SN - 1792-1074 1792-1082 SP - 213 ST - Expression levels and clinical significance of miR‑203 and miR‑133b in laryngeal carcinoma T2 - Oncology Letters TI - Expression levels and clinical significance of miR‑203 and miR‑133b in laryngeal carcinoma UR - https://doi.org/10.3892/ol.2020.12076 VL - 20 ER -